Article Text

other Versions

MicroRNA-29a Regulates Intestinal Membrane Permeability in Patients with Irritable Bowel Syndrome
  1. QiQi Zhou,
  2. Wiley W Souba,
  3. Carlo M Croce,
  4. G. Nicholas Verne*
  1. 1 Ohio State University, United States
  1. Correspondence to: G. Nicholas Verne, Ohio State University, 1799 West 5th Ave, Columbus, 43212, United States; ginick{at}


Background: The molecular mechanisms underlying the pathophysiology of irritable bowel syndrome (IBS) are poorly understood. One mechanism may involve increased intestinal permeability that is reversed with glutamine supplementation. Our goal was to evaluate the expression of glutamine synthetase and its complementary miRNA in blood microvesicles and gut tissues of IBS patients with increased intestinal membrane permeability.

Methods: We evaluated 19 diarrhea-predominant IBS patients and 10 controls for intestinal membrane permeability using the lactulose/mannitol method. miRNA expression was evaluated in blood microvesicles and gut tissue. To further confirm the relationship between miRNA and glutamine synthetase expression, cell culture experiments were conducted. Glutamine synthetase was also evaluated in the gut tissues of patients.

Results: A subset of IBS patients (8/19, 42%) had increased intestinal membrane permeability and decreased glutamine synthetase expression compared to IBS patients with normal membrane permeability and to controls. Expression of miR-29a was increased in blood microvesicles, small bowel and colon tissues of IBS patients with increased intestinal membrane permeability. Increased intestinal permeability was modulated by miR-29a which has a complementary site in the 3'-UTR of the GLUL gene.

Conclusions: The results support the conclusion that GLUL regulates intestinal membrane permeability and miR-29a regulates both GLUL and intestinal membrane permeability. The data suggests that miR-29a effects on intestinal membrane permeability may be due to its regulation of GLUL. Targeting this signaling pathway could lead to a new therapeutic approach to the treatment of patients with IBS, especially because small molecules that mimic or inhibit miRNA-based mechanisms are readily available.

Statistics from

  • Web only appendix


      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Linked Articles